“Embedded in Lupin is a formula for growth which fuels creativity, performance and innovation”
It was Dr. Desh Bandhu Gupta’s vision and passion which helped him grow a small dream into a large company with a global footprint.
The most advanced pharmaceutical product development
Developing new chemical entities for focused therapy areas
Producing quality medicines in areas of
Producing high quality affordable
and accessible biologics
Technological progress and scientific advancements continue to transform lives and disrupt businesses. Additionally, pharmaceutical business paradigms are also being impacted by factors beyond the conventional forces such as aging populations, spiraling healthcare costs, increase in chronic diseases or change in disease patterns. The industry needs to embrace new advances in digital technology, communications, systems and software. The global pharmaceutical industry is on the cusp of an era of significant transformation.
The world of life sciences is converging like never before and the convergence of pharmaceutical, biotechnology and medical technology would improve outcomes that could dramatically alter drug development and delivery.
At Lupin, we are embracing advanced technologies, scientific breakthroughs and partnerships that enable us to advance research and development towards building a diversified portfolio and gain a leadership position in important new product introductions. Our Research & Development helps build a solid foundation as we progress to become a Complex Generics, Biosimilars and Specialty frontrunner.
Lupin’s investments in Research and Development (R&D) have helped us gain a leadership position in differentiated product introductions and become a formidable player in the generics space. It forms the base for further successes as we emerge gradually as a specialty pharmaceutical player. These investments are calibrated for risks and appropriate returns and encompass not merely the developed markets like US and Europe but also the emerging markets.
Lupin has a solid team of 1,700 scientists and technologists employed at state-of-the-art facilities in India and abroad. We are well on track to emerge as an innovation led transnational pharmaceutical powerhouse providing affordable healthcare solutions with uncompromising quality. Lupin’s research scientists have a proven track record of delivering high-quality technology-intensive products, Active Pharmaceutical Ingredients (APIs), Formulations and newer dispensation forms.
Keeping our focus on research-led financial growth, we make well-calibrated investments in Research & Development. This continues to drive our efforts in finding novel solutions and ramp up efforts on a range of delivery systems spanning multiple concepts and solutions.
The scientists in Research & Development, work closely with the respective business teams to generate innovative concepts and ideas, exploring both the unmet market and synergies across therapeutic areas. We focus on areas like Complex Generics, Novel Drug Discovery and Development (NDDD) and Biotechnology.
Vinita Gupta is the CEO of Lupin Limited (Lupin) and Chairperson of Lupin Inc., (LI) and its US subsidiary, Lupin Pharmaceutical Inc. (LPI).
Vinita is a graduate in pharmacy from the University of Mumbai and earned an MBA degree at the Kellogg School of Management at Northwestern University. Vinita has been instrumental in formulating and executing a strategy that has helped the company emerge as a global pharmaceutical powerhouse; amongst the most exciting growth stories in the pharmaceutical industry. Through a combination of organic growth and strategic acquisitions, she has led the company’s global expansion plans. In particular, she founded, led and established Lupin’s largest region, the United States.
Vinita has been regularly named by Forbes Asia in its Top 50 Power Business women listings for Asia Pacific. Vinita was also recognized by Business Today Hall of Fame – Most Powerful Women in Business in 2016 and was recently named Outstanding Business Woman Leader of the Year by CNBC India Business Leader Awards. She was the winner of the inaugural EY, U.S. 2012 Family Business Award of Excellence and EY Entrepreneur Of the Year® 2012 award winner for Health Services and Technology in Maryland. She is regarded as amongst the most influential Indian Business Women globally.
Vinita along with her brother Nilesh (Managing Director, Lupin Limited) were named Ernst & Young (EY) Entrepreneur of The Year 2015 and won the Forbes India Leadership Awards 2016, Entrepreneur of the Year.
In 2017 Vinita was appointed to the board of directors for Intrexon Corporation. She is also a member of the Global Advisory Board at the Kellogg School of Management at Northwestern University.
Mr. Nilesh Gupta is the MD of Lupin Limited and a member of the Board of Directors. Having joined Lupin in 1996, Mr. Gupta led Lupin’s research, supply chain, manufacturing, quality and regulatory operations, and took charge as the company’s Managing Director in 2013. He has not only been responsible for transforming Lupin’s research program and expanding the company’s manufacturing operations but has also been instrumental in formulating and executing the core strategy that has helped Lupin emerge as a global specialty pharmaceutical major.
Mr. Gupta, along with his sister Vinita Gupta, won the Entrepreneur of the Year award at Forbes India Leadership Awards in 2016 as well as Ernst & Young ‘Entrepreneur of the Year Award’ in India in 2015, also with his sister Vinita Gupta.
Mr. Gupta is a Chemical Engineer from the University Department of Chemical Technology (UDCT) (now ICT), Mumbai, and a graduate with honours from the Wharton School, University of Pennsylvania, USA, where he specialized in healthcare, strategic management and finance.